| Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells MG Lechner, DJ Liebertz, AL Epstein The Journal of Immunology 185 (4), 2273-2284, 2010 | 697 | 2010 |
| Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases GS Brody, D Deapen, CR Taylor, L Pinter-Brown, SR House-Lightner, ... Plastic and reconstructive surgery 135 (3), 695-705, 2015 | 421 | 2015 |
| Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy MG Lechner, SS Karimi, K Barry-Holson, TE Angell, KA Murphy, ... Journal of immunotherapy 36 (9), 477-489, 2013 | 402 | 2013 |
| Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured … MG Lechner, C Megiel, SM Russell, B Bingham, N Arger, T Woo, ... Journal of translational medicine 9, 1-20, 2011 | 255 | 2011 |
| Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, A Achufusi, P Armand, ... Journal of the National Comprehensive Cancer Network 20 (4), 387-405, 2022 | 203 | 2022 |
| MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro TE Angell, MG Lechner, JK Jang, JS LoPresti, AL Epstein Clinical Cancer Research 20 (23), 6034-6044, 2014 | 156 | 2014 |
| Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study TE Angell, MG Lechner, CT Nguyen, VL Salvato, JT Nicoloff, JS LoPresti The Journal of Clinical Endocrinology & Metabolism 100 (2), 451-459, 2015 | 146 | 2015 |
| Survival Signals and Targets for Therapy in Breast Implant–Associated ALK− Anaplastic Large Cell Lymphoma MG Lechner, C Megiel, CH Church, TE Angell, SM Russell, RB Sevell, ... Clinical Cancer Research 18 (17), 4549-4559, 2012 | 138 | 2012 |
| Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma SM Russell, TE Angell, MG Lechner, DJ Liebertz, AJ Correa, UK Sinha, ... Head & neck oncology 5 (3), 24, 2013 | 131 | 2013 |
| BRAFV600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration TE Angell, MG Lechner, JK Jang, AJ Correa, JS LoPresti, AL Epstein Thyroid 24 (9), 1385-1393, 2014 | 130 | 2014 |
| Breast implant‐associated, ALK‐negative, T‐cell, anaplastic, large‐cell lymphoma: Establishment and characterization of a model cell line (TLBR‐1) for this newly emerging … MG Lechner, S Lade, DJ Liebertz, HM Prince, GS Brody, HR Webster, ... Cancer 117 (7), 1478-1489, 2011 | 85 | 2011 |
| Sex differences in immunity NM Wilkinson, HC Chen, MG Lechner, MA Su Annual review of immunology 40, 75-94, 2022 | 78 | 2022 |
| Circulating myeloid-derived suppressor cells predict differentiated thyroid cancer diagnosis and extent TE Angell, MG Lechner, AM Smith, SE Martin, SG Groshen, DR Maceri, ... Thyroid 26 (3), 381-389, 2016 | 74 | 2016 |
| Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors MG Lechner, SM Russell, RS Bass, AL Epstein Immunotherapy 3 (11), 1317-1340, 2011 | 68 | 2011 |
| Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1 DJ Liebertz, MG Lechner, R Masood, UK Sinha, J Han, RK Puri, ... Head & neck oncology 2, 1-14, 2010 | 53 | 2010 |
| Finding consensus after two decades of breast implant-associated anaplastic large cell lymphoma MW Clemens, RC DeCoster, B Fairchild, AA Bessonov, FS Di Pompeo Seminars in Plastic Surgery 33 (04), 270-278, 2019 | 47 | 2019 |
| An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas KA Murphy, MG Lechner, FE Popescu, J Bedi, SA Decker, P Hu, ... Clinical Cancer Research 18 (17), 4657-4668, 2012 | 47 | 2012 |
| Gene expression in primate liver during viral hemorrhagic fever M Djavani, OR Crasta, Y Zhang, JC Zapata, B Sobral, MG Lechner, ... Virology Journal 6, 1-18, 2009 | 42 | 2009 |
| Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients MG Lechner, CM Vyas, OPR Hamnvik, EK Alexander, PR Larsen, ... Thyroid 28 (4), 437-444, 2018 | 40 | 2018 |
| Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers MG Lechner, CM Vyas, OPR Hamnvik, EK Alexander, PR Larsen, ... Thyroid 28 (4), 445-453, 2018 | 36 | 2018 |
